Free PANRE Practice Questions

Renal/Urology PANRE practice questions

10 free, board-style Renal/Urology questions for the PANRE, each with the correct answer and a complete explanation. No email, no account required.

Renal/Urology is 9% of the PANRE content blueprint: NCCPA lists Renal System (4%) and Genitourinary System (5%) separately, and this page covers both. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.

Question 1RenalMedium
A 45-year-old man presents after his second calcium oxalate kidney stone. A 24-hour urine collection shows urinary citrate 120 mg/day (low; normal greater than 320 mg/day), normal calcium and oxalate, and urine pH 6.4. Stone analysis confirms calcium oxalate monohydrate. Which of the following is the most appropriate pharmacotherapy to prevent recurrence?
  • APotassium citrate
  • BSodium bicarbonate
  • CAcetazolamide
  • DAllopurinol
  • EHydrochlorothiazide
Reveal answer & full explanation
Correct answer: A — Potassium citrate
  • APotassium citrate✓
  • BSodium bicarbonate
  • CAcetazolamide
  • DAllopurinol
  • EHydrochlorothiazide

Why Potassium citrate is correct

  • The 24-hour urine shows isolated hypocitraturia (citrate 120 mg/day) with normal calcium and oxalate.
  • Citrate binds urinary calcium and raises urine pH, inhibiting calcium oxalate and calcium phosphate crystallization; potassium citrate is first-line for hypocitraturia per current urologic guidance.
  • Fluid intake above 2.5 L/day remains the cornerstone measure for all stone types.

Why the others are wrong

  • Sodium bicarbonate - an alkali that can raise urinary citrate, but its sodium load increases urinary calcium excretion, so it is reserved for patients who cannot tolerate a potassium salt (right-alkali, wrong-salt trap).
  • Allopurinol - used for hyperuricosuria or uric acid stones, neither of which is present here (buzzword trap on 'stones').
  • Hydrochlorothiazide - reduces urinary calcium and is first-line for hypercalciuria, but calcium excretion is normal here (premature closure on the most common stone therapy).
  • Acetazolamide - a carbonic anhydrase inhibitor that alkalinizes the urine, which can make it look like a substitute for citrate therapy, but the metabolic acidosis it causes lowers urinary citrate further and promotes calcium phosphate stones (alkalinization-without-citrate trap).
Question 2RenalMedium
A 65-year-old male with CKD stage 4 (eGFR 18, declining 4 mL/min/year) is referred for nephrology evaluation. His 45-year-old son is willing to donate a kidney. Which of the following best describes when transplant evaluation should ideally begin?
  • AWhen uremic symptoms develop
  • BWhen eGFR is below 10 mL/min
  • CWhen eGFR is at or below 20 mL/min
  • DAfter dialysis is initiated
  • EWhen eGFR is below 15 mL/min
Reveal answer & full explanation
Correct answer: C — When eGFR is at or below 20 mL/min
  • AWhen uremic symptoms develop
  • BWhen eGFR is below 10 mL/min
  • CWhen eGFR is at or below 20 mL/min✓
  • DAfter dialysis is initiated
  • EWhen eGFR is below 15 mL/min

Why When eGFR is at or below 20 mL/min is correct

  • Pre-emptive kidney transplantation (transplant before dialysis) yields the best outcomes: better graft and patient survival, lower delayed graft function, and avoidance of dialysis morbidity
  • KDIGO 2020 advises referral for transplant evaluation at least 6-12 months before anticipated dialysis (with transplant education once eGFR falls below 30), and under OPTN policy deceased-donor waiting time begins to accrue once eGFR is at or below 20 mL/min/1.73m²
  • Evaluation should start early — workup takes 3-6 months, and living donor workup takes 6-12 months

Why the others are wrong

  • When eGFR is below 15 mL/min — waiting until eGFR is below 15 risks the patient beginning dialysis before transplant evaluation and workup are complete
  • When eGFR is below 10 mL/min — too late; pre-emptive transplant opportunity is likely lost
  • After dialysis is initiated — post-dialysis transplant has significantly worse outcomes compared to pre-emptive transplant
  • When uremic symptoms develop — tempting because dialysis initiation is timed to uremic symptoms rather than a specific eGFR, but transplant evaluation must start well before uremia so the recipient and living-donor workups are finished in time for a pre-emptive transplant

Additional high-yield points

  • Living donor kidneys have significantly better outcomes than deceased donor kidneys: 10-year all-cause graft survival is roughly 60-65% versus about 45-55%
  • Age 65 is not a contraindication to transplant — functional status and comorbidities matter more than chronological age
Question 3RenalMedium
A 60-year-old male with diabetes mellitus, hypertension, and chronic kidney disease (CKD) stage 3 (eGFR 42) has a creatinine of 1.8 and is starting an ACE inhibitor (ACEi). Creatinine rises to 2.1 (17% increase) over 2 weeks. Potassium is 4.8. He is otherwise well. Which of the following is the most appropriate next step?
  • ADiscontinue the ACE inhibitor
  • BSwitch the ACE inhibitor to amlodipine
  • CContinue the ACE inhibitor and monitor
  • DAdd an ARB to the ACE inhibitor
  • EHalve the ACE inhibitor dose
Reveal answer & full explanation
Correct answer: C — Continue the ACE inhibitor and monitor
  • ADiscontinue the ACE inhibitor
  • BSwitch the ACE inhibitor to amlodipine
  • CContinue the ACE inhibitor and monitor✓
  • DAdd an ARB to the ACE inhibitor
  • EHalve the ACE inhibitor dose

Why Continue the ACE inhibitor and monitor is correct

  • ACE inhibitor (ACEi) and angiotensin receptor blocker (ARB) dilate the efferent arteriole, reducing glomerular hydraulic pressure and GFR acutely — this is the mechanism of long-term renoprotection (reduces hyperfiltration)
  • A creatinine rise of up to 30% from baseline within 4 weeks (KDIGO 2024) is expected and acceptable
  • This patient has a 17% rise — within the acceptable range; continue ACEi if the creatinine rise stays at or below 30%
  • Potassium of 4.8 is normal and does not warrant stopping the ACEi

Why the others are wrong

  • Discontinue the ACE inhibitor — discontinuation is considered when creatinine rises more than 30% within 4 weeks, bilateral renal artery stenosis (RAS) is suspected, or potassium stays above 5.5 despite treatment; none of those apply here
  • Switch the ACE inhibitor to amlodipine — switching abandons proven renoprotection for a 17% rise that is well within the acceptable threshold
  • Halve the ACE inhibitor dose — dose reduction is not indicated for an acceptable creatinine rise and would reduce the renoprotective benefit
  • Add an ARB to the ACE inhibitor — dual RAAS blockade was once used to push proteinuria lower in diabetic kidney disease, but ONTARGET and VA NEPHRON-D showed more hyperkalemia and acute kidney injury without renal benefit, so guidelines advise against combining an ACEi with an ARB; with creatinine already up 17% and potassium 4.8, adding one would compound both risks

Additional high-yield points

  • Stop ACEi/ARB if: creatinine rise above 30% within 4 weeks, bilateral RAS suspected (bilateral RAS causes a dramatic GFR drop), or persistent K >5.5 despite treatment
  • Renoprotection evidence: ACEi/ARBs reduce proteinuria, slow chronic kidney disease (CKD) progression, and reduce end-stage renal disease (ESRD) risk in diabetes mellitus (DM) — renal benefits vastly outweigh the acceptable acute GFR decline
Question 4RenalMedium
A 68-year-old female with stage 3b chronic kidney disease (CKD) (eGFR 34) and type 2 diabetes mellitus (T2DM) has calcium 11.2 mg/dL and parathyroid hormone (PTH) 12 pg/mL (suppressed). She is on calcium carbonate 1000mg BID and vitamin D3 1000 IU daily. Malignancy workup is negative. Which of the following is the most likely cause of her hypercalcemia?
  • AMilk-alkali syndrome
  • BVitamin D toxicity
  • CGranulomatous hypercalcemia
  • DThyrotoxic hypercalcemia
  • EPaget disease of bone
Reveal answer & full explanation
Correct answer: A — Milk-alkali syndrome
  • AMilk-alkali syndrome✓
  • BVitamin D toxicity
  • CGranulomatous hypercalcemia
  • DThyrotoxic hypercalcemia
  • EPaget disease of bone

Why Milk-alkali syndrome is correct

  • Milk-alkali (calcium-alkali) syndrome is the triad of hypercalcemia, metabolic alkalosis, and renal insufficiency from excessive calcium and alkali intake
  • This patient is taking calcium carbonate 1000 mg BID, now the predominant modern cause; calcium carbonate causes alkalosis, decreased renal calcium excretion, and hypercalcemia
  • PTH is suppressed (12 pg/mL) by feedback inhibition, which distinguishes this from primary hyperparathyroidism
  • It is the third most common cause of hypercalcemia after primary hyperparathyroidism and malignancy

Why the others are wrong

  • Granulomatous hypercalcemia — Also PTH-independent, but it results from unregulated 1-alpha-hydroxylase activity in granuloma macrophages (sarcoidosis, tuberculosis, fungal infection) that raises calcitriol; nothing in the vignette suggests granulomatous disease, and her calcium carbonate intake explains the picture (confused-with a calcitriol-mediated cause)
  • Vitamin D toxicity — A possible minor contributor given D3 supplementation, but the calcium carbonate load with the alkalosis pattern is the primary driver (anchoring)
  • Thyrotoxic hypercalcemia — Excess thyroid hormone increases osteoclastic bone resorption and can cause mild PTH-independent hypercalcemia, but nothing in the vignette suggests hyperthyroidism, whereas her calcium carbonate load with reduced kidney function fully accounts for it (zebra over the common cause)
  • Paget disease of bone — an older patient may bring Paget disease to mind as a bone-turnover cause, but serum calcium and phosphate are typically normal in Paget disease, whose hallmark is an isolated elevated alkaline phosphatase; hypercalcemia occurs mainly with immobilization, and her calcium carbonate load with reduced kidney function explains the picture (confused-with a high-bone-turnover cause)

Additional high-yield points

  • Management: discontinue calcium carbonate and vitamin D; IV normal saline; monitor calcium, creatinine, bicarbonate; switch to a non-calcium phosphate binder (sevelamer, lanthanum, sucroferric oxyhydroxide, ferric citrate)
  • Calcium normalizes in days; bisphosphonates rarely needed
Question 5RenalMedium
A 24-year-old sexually active man presents with dysuria and yellow urethral discharge for 3 days. Gram stain of the discharge reveals gram-negative intracellular diplococci. He is treated with intramuscular ceftriaxone and oral doxycycline. He returns 2 weeks later with right scrotal pain and swelling. Which of the following is the most likely complication of his initial infection?
  • AEpididymitis
  • BIsolated orchitis
  • CAcute prostatitis
  • DFournier gangrene
  • EProstate abscess
Reveal answer & full explanation
Correct answer: A — Epididymitis
  • AEpididymitis✓
  • BIsolated orchitis
  • CAcute prostatitis
  • DFournier gangrene
  • EProstate abscess

Why Epididymitis is correct

  • This patient had gonococcal urethritis; the most common local complication in young sexually active men is acute epididymitis from retrograde ascent of organisms through the vas deferens.
  • Untreated or partially treated urethritis from Neisseria gonorrhoeae or Chlamydia trachomatis can extend up the genital tract, producing unilateral scrotal pain, swelling, and tenderness consistent with this presentation.
  • Epididymitis is by far the most frequent complication of sexually transmitted urethritis in men under 35.

Why the others are wrong

  • Isolated orchitis — orchitis without epididymal involvement is uncommon and usually viral (classically mumps); bacterial orchitis almost always arises by contiguous spread from the epididymis, so ascending gonococcal or chlamydial infection causes epididymitis or epididymo-orchitis rather than isolated orchitis (confused-with adjacent structure).
  • Fournier gangrene — a rare necrotizing fasciitis of the perineum seen in immunocompromised or diabetic patients, not a typical urethritis sequela (anchoring on rare complication).
  • Prostate abscess — rare and typically occurs in older men or those with diabetes or instrumentation rather than as a routine complication of urethritis (premature closure).
  • Acute prostatitis — urethral infection can ascend to the prostate, but acute bacterial prostatitis typically causes fever, perineal or low back pain, and voiding symptoms with a tender prostate rather than unilateral scrotal pain and swelling, and it is much less common than epididymitis in young men (confused-with ascending infection site).
Question 6RenalMedium
A 45-year-old male with chronic kidney disease (CKD) stage 3 (eGFR 32) develops fever, polyarthritis, and a purpuric rash on the lower legs. Urinalysis shows RBC casts and 3+ proteinuria. A refrigerated serum sample forms a precipitate that redissolves on rewarming; C4 is undetectable, C3 is low, and rheumatoid factor is positive. Hepatitis C virus (HCV) antibody is positive with viral load 2.4 million IU/mL. Which of the following is the most likely diagnosis?
  • AMembranous nephropathy
  • BIgA vasculitis nephropathy
  • CLupus nephritis class IV
  • DPolyarteritis nodosa
  • ECryoglobulinemic vasculitis
Reveal answer & full explanation
Correct answer: E — Cryoglobulinemic vasculitis
  • AMembranous nephropathy
  • BIgA vasculitis nephropathy
  • CLupus nephritis class IV
  • DPolyarteritis nodosa
  • ECryoglobulinemic vasculitis✓

Why Cryoglobulinemic vasculitis is correct

  • Hepatitis C virus (HCV) accounts for 80–90% of mixed cryoglobulinemic vasculitis, and this patient has a high HCV viral load.
  • Type II cryoglobulins (monoclonal IgM with rheumatoid factor activity plus polyclonal IgG) are most common.
  • Classic triad: palpable purpura, arthralgias, and weakness; peripheral neuropathy and membranoproliferative-pattern glomerulonephritis also occur.
  • Lab hallmarks: low C4 disproportionate to C3, positive rheumatoid factor, and serum cryoglobulins (immunoglobulins that precipitate in refrigerated serum and redissolve on rewarming) — all present here.
  • Renal involvement produces RBC casts and proteinuria from subendothelial immune-complex deposition.

Why the others are wrong

  • IgA vasculitis nephropathy — IgA-driven small-vessel vasculitis without an HCV link, cryoglobulins, or the low-C4 pattern (confused-with, shared purpura).
  • Lupus nephritis class IV — Systemic lupus erythematosus shows anti-dsDNA and lacks serum cryoglobulins or rheumatoid factor positivity (confused-with immune-complex GN).
  • Membranous nephropathy — Presents with bland nephrotic-range proteinuria, not palpable purpura, arthritis, or an active urine sediment (right-concept-wrong-setting).
  • Polyarteritis nodosa — the vasculitis classically linked to hepatitis B, so it is tempting in a febrile patient with viral hepatitis and arthritis, but HCV-associated cases are rare, it involves medium-sized arteries and spares the glomeruli (renal infarcts and renovascular hypertension rather than RBC casts), and it does not produce serum cryoglobulins (confused-with the hepatitis-B-associated vasculitis).

Additional high-yield points

  • Treatment: direct-acting antiviral (DAA) therapy for HCV (sofosbuvir/velpatasvir or elbasvir/grazoprevir); sustained virologic response clears cryoglobulins in over 90% with vasculitis improvement.
  • Severe disease (rapidly progressive glomerulonephritis, severe neuropathy): rituximab plus glucocorticoids plus plasma exchange before or alongside DAA therapy.
Question 7RenalMedium
A 35-year-old female with autosomal dominant polycystic kidney disease (ADPKD) is referred for management. eGFR is 62 mL/min. Total kidney volume on MRI is 2,200 mL (Mayo Imaging Classification 1C). She has no pain or other complications. She asks about disease-modifying treatment to slow cyst growth and preserve renal function. Which of the following is the most appropriate disease-modifying therapy?
  • ASpironolactone
  • BFurosemide
  • COctreotide
  • DLisinopril
  • ETolvaptan
Reveal answer & full explanation
Correct answer: E — Tolvaptan
  • ASpironolactone
  • BFurosemide
  • COctreotide
  • DLisinopril
  • ETolvaptan✓

Why Tolvaptan is correct

  • Autosomal dominant polycystic kidney disease (ADPKD) results from mutations in PKD1 or PKD2 (encoding polycystin-1 and polycystin-2).
  • Tolvaptan is a selective vasopressin V2 receptor antagonist; V2 receptor activation raises intracellular cAMP, which drives cyst epithelial proliferation and fluid secretion, so V2 blockade slows cyst growth.
  • TEMPO 3:4 trial (NEJM 2012): tolvaptan reduced total kidney volume (TKV) growth by 49% and eGFR decline by 26% over 3 years.
  • REPRISE trial confirmed benefit in moderate chronic kidney disease (CKD) (eGFR 25-65).
  • Patient selection targets rapidly progressing disease (Mayo Class 1C-1E); this patient is Mayo Class 1C.

Why the others are wrong

  • Furosemide — Right-concept-wrong-mechanism: a loop diuretic reduces volume overload but has no disease-modifying effect on cyst growth in ADPKD.
  • Lisinopril — Confused-with BP management: an ACE inhibitor is first-line for blood pressure and proteinuria control in ADPKD, and intensive BP control in HALT-PKD Study A (ages 15-49 with eGFR >60; home BP target 95/60 to 110/75 mm Hg) only modestly slowed kidney-volume growth, but ACE inhibition is not the cyst-targeted disease-modifying therapy used for rapidly progressing disease.
  • Spironolactone — Anchoring on diuretics: a mineralocorticoid antagonist has no established disease-modifying role in ADPKD cyst growth.
  • Octreotide — right-pathway-wrong-drug: like tolvaptan, a somatostatin analog lowers cyst cAMP and has been studied in ADPKD, but its established role is reducing liver volume in symptomatic polycystic liver disease; it is not approved to slow kidney function decline in ADPKD, and she has no liver complications.

Additional high-yield points

  • Tolvaptan side effects: aquaresis (polyuria, polydipsia, nocturia) and hepatotoxicity — requires a REMS program with monthly liver function tests (LFTs) for 18 months.
  • Contraindications: liver disease, pregnancy, inability to maintain adequate fluids.
  • Adjuncts: low-sodium diet, moderate protein intake (about 0.8-1.0 g/kg/day; avoid both high-protein and protein-restricted diets), avoid excessive caffeine, and adequate water intake.
Question 8RenalEasy
A 55-year-old man with benign prostatic hyperplasia reports urinary frequency, nocturia four times nightly, and a weak stream. He has not tried any medications. Post-void residual volume is 250 mL and the International Prostate Symptom Score is 22 (severe). Which of the following is the most appropriate first-line pharmacotherapy?
  • AOxybutynin
  • BTadalafil
  • CBethanechol
  • DTamsulosin
  • EFinasteride
Reveal answer & full explanation
Correct answer: D — Tamsulosin
  • AOxybutynin
  • BTadalafil
  • CBethanechol
  • DTamsulosin✓
  • EFinasteride

Why Tamsulosin is correct

  • Alpha-1 blockers relax prostatic and bladder-neck smooth muscle, giving the most rapid symptom relief (days to weeks) in benign prostatic hyperplasia.
  • With severe symptoms (IPSS 22) and no prior therapy, an alpha-blocker is appropriate first-line monotherapy per current urologic guidance.
  • It improves urinary flow without the months-long delay of prostate-shrinking agents.

Why the others are wrong

  • Tadalafil — a PDE5 inhibitor approved for BPH symptoms regardless of erectile dysfunction, but it carries a weaker (conditional) AUA recommendation than alpha-blockers and does not meaningfully improve peak urinary flow or post-void residual (buzzword trap on 'approved for BPH').
  • Finasteride — a 5-alpha-reductase inhibitor that shrinks large prostates over 6-12 months; its onset is too slow for prompt relief (right-class, wrong-timing).
  • Oxybutynin — an anticholinergic for overactive bladder that can precipitate urinary retention given the elevated post-void residual (anchoring on storage symptoms).
  • Bethanechol — a muscarinic agonist used for urinary retention from an underactive detrusor, so the elevated post-void residual makes it tempting; here the residual reflects prostatic outlet obstruction, which bethanechol does not relieve and which is a contraindication to its use (retention-mechanism trap).
Question 9RenalMedium
A 14-year-old male develops sudden severe pain and swelling in the right testicle at 2 AM while sleeping. The right testis is exquisitely tender and elevated. He has no penile discharge or dysuria, and the left testicle is normal. Doppler ultrasound shows absent blood flow in the right testis. Which of the following is the most likely diagnosis?
  • ATesticular torsion
  • BEpididymo-orchitis
  • CSegmental testicular infarct
  • DIncarcerated inguinal hernia
  • ETorsion of appendix testis
Reveal answer & full explanation
Correct answer: A — Testicular torsion
  • ATesticular torsion✓
  • BEpididymo-orchitis
  • CSegmental testicular infarct
  • DIncarcerated inguinal hernia
  • ETorsion of appendix testis

Why Testicular torsion is correct

  • Torsion of the spermatic cord cuts off testicular blood supply, causing sudden severe scrotal pain (often at night or during activity), nausea/vomiting, and a high-riding, transverse-lying testis.
  • Peak incidence is in neonates and adolescents ages 12–18; the key risk factor is a bell-clapper deformity.
  • Doppler ultrasound showing absent blood flow confirms the diagnosis.
  • An absent cremasteric reflex is the most sensitive physical exam sign.

Why the others are wrong

  • Torsion of appendix testis — confused-with a torsion mimic; it peaks in prepubertal boys ages 7 to 12 and causes more gradual pain with focal tenderness at the upper pole (sometimes a blue dot sign), while the testis keeps a normal lie, the cremasteric reflex is preserved, and Doppler shows normal or increased testicular flow rather than absent flow.
  • Epididymo-orchitis — right-concept-wrong-setting; it has gradual onset with an intact cremasteric reflex and increased Doppler flow (hyperemia), the opposite of the absent flow seen here.
  • Incarcerated inguinal hernia — confused-with an acute groin emergency; it presents as a tender, irreducible bulge in the inguinal canal that may extend into the scrotum, with the testis palpable separately below it, whereas here the pain and swelling localize to an elevated, exquisitely tender testis with absent intratesticular flow.
  • Segmental testicular infarct — confused-with an ischemic torsion mimic; it also causes acute testicular pain with an avascular area on Doppler, but it usually affects adult men, is often idiopathic or linked to sickle cell disease, vasculitis, or a hypercoagulable state, and its avascular zone is focal (wedge-shaped or round) with flow preserved in the rest of the testis, whereas here flow is absent throughout an elevated testis, the signature of a twisted spermatic cord.

Additional high-yield points

  • Time to salvage: within 6 hours 90–100%; 6–12 hours 50–70%; 12–24 hours 20–50%; >24 hours <10%.
  • Diagnosis is clinical — do not delay surgery for imaging when suspicion is high.
  • Management: emergent scrotal exploration; manual detorsion at bedside (rotate outward toward the thigh) as a temporizing measure; bilateral orchiopexy to prevent recurrence; orchiectomy if the testis is necrotic.
Question 10RenalMedium
A 58-year-old diabetic woman presents with 3 days of urgency, frequency, and flank pain. Temperature is 38.8°C, HR 104. Urinalysis shows large leukocyte esterase, nitrites, many WBCs, and WBC casts. Urine culture grows E. coli, and local fluoroquinolone resistance among E. coli is below 10%. She is hemodynamically stable and tolerating oral intake. What is the most appropriate treatment?
  • AOral TMP-SMX DS for 3 days
  • BOral ciprofloxacin for 7 days
  • COral moxifloxacin for 7 days
  • DOral amoxicillin for 7 days
  • EOral nitrofurantoin for 5 days
Reveal answer & full explanation
Correct answer: B — Oral ciprofloxacin for 7 days
  • AOral TMP-SMX DS for 3 days
  • BOral ciprofloxacin for 7 days✓
  • COral moxifloxacin for 7 days
  • DOral amoxicillin for 7 days
  • EOral nitrofurantoin for 5 days

Why Oral ciprofloxacin for 7 days is correct

  • Pyelonephritis is an upper urinary tract infection (UTI) characterized by flank pain, fever, and WBC casts (pathognomonic of renal origin)
  • Mild-to-moderate pyelonephritis in a hemodynamically stable outpatient tolerating oral intake is treated with oral ciprofloxacin for 7 days
  • Trimethoprim-sulfamethoxazole (TMP-SMX) for 7 days is an alternative if the organism is susceptible

Why the others are wrong

  • Oral nitrofurantoin for 5 days — nitrofurantoin does not achieve adequate renal tissue concentrations and is not appropriate for pyelonephritis; it is used only for uncomplicated lower UTIs
  • Oral TMP-SMX DS for 3 days — a 3-day course of double-strength (DS) TMP-SMX is the regimen for uncomplicated cystitis; pyelonephritis needs a longer course (7 days of TMP-SMX when the isolate is susceptible), so 3 days risks treatment failure and relapse
  • Oral amoxicillin for 7 days — aminopenicillins such as amoxicillin have high E. coli resistance rates and poor empiric reliability for pyelonephritis
  • Oral moxifloxacin for 7 days — a fluoroquinolone like ciprofloxacin, so the low local fluoroquinolone resistance makes it look equivalent, but moxifloxacin is eliminated largely by nonrenal routes and reaches low urinary concentrations, so it is not recommended for UTI or pyelonephritis; ciprofloxacin and levofloxacin are the fluoroquinolones used for urinary infections

Additional high-yield points

  • If local fluoroquinolone resistance exceeds 10%, give a one-time dose of a long-acting parenteral agent such as ceftriaxone 1 g IV before starting the oral course

That's 10 of 7,700+. Get the rest.

Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → See today's free PANRE question →

Renal/Urology PANRE practice: FAQ

Are these Renal/Urology PANRE practice questions free?

Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.

How much of the PANRE is Renal/Urology?

Renal/Urology makes up 9% of the PANRE content blueprint (NCCPA's Renal System, 4%, plus Genitourinary System, 5%). FirstPassPA's timed PANRE exams are dealt to the same weights, so a practice exam carries the same share of Renal/Urology questions.

How should I use these questions?

Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Renal/Urology questions in the app, or take a full timed PANRE practice exam dealt to the blueprint weights.

Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.